The week in health tech, explained in plain English.Get the free newsletter →
October 25, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Hospitals

AMA Votes to Reject the Term 'Provider' for Physicians

The American Medical Association's House of Delegates voted this week at its Annual Meeting in Chicago to formally oppose use of the term "provider" when referring to physicians, according to Becker's Hospital Review.

The new policy extends existing AMA guidance that already asks healthcare organizations to specify the type of clinician involved in patient care, using each professional's recognized title rather than a generic catch-all. The AMA argues that lumping physicians, nurse practitioners, physician assistants, and others under one word obscures differences in training and licensure that matter to patients.

In practice, the vote is a signal rather than a mandate. The AMA cannot force hospitals, insurers, or electronic health record systems to drop the word, and "provider" remains deeply embedded in billing codes, contracts, and federal regulation. Still, the policy gives physician advocates leverage to push health systems and vendors toward more precise language in documentation, patient-facing materials, and staffing models.

More in Hospitals

Hospitals

Visitor Fatally Shot at HCA Missouri Hospital; Patient Charged

A visitor was fatally shot at HCA Healthcare's Centerpoint Medical Center in Missouri, and patient James Lawson faces second-degree murder charges.

Why it matters: Violence inside hospitals is driving systems to rethink weapons screening and access control to protect patients, staff, and visitors.

Hospitals

Pay Dispute Puts Illinois Hospital's Trauma Status at Risk

An Illinois hospital's level 2 trauma designation is under state review after its anesthesia group suspended services over a missed payment.

Why it matters: A single vendor contract breakdown can strip a hospital of its trauma status and leave a community without nearby emergency surgical care.

Hospitals

Merck-Moderna mRNA Cancer Vaccine Cuts Melanoma Risk 42%

Merck and Moderna's personalized mRNA cancer vaccine cut melanoma recurrence or death by 42% in a phase 3 trial when paired with Keytruda immunotherapy.

Why it matters: A successful phase 3 readout signals that personalized mRNA cancer vaccines are nearing clinical reality for high-risk cancer patients.